SAN FRANCISCO — Biogen wish to make further biotech acquisitions in 2025 past Friday’s provide to purchase its financially troubled companion Sage Therapeutics, chief govt Chris Viehbacher instructed me Sunday.
“We will probably be doing offers — the dimensions of these offers, I can not say,” he stated in an interview forward of the J.P. Morgan Healthcare Convention.
Biogen supplied to purchase Sage, its advertising companion on Zurzuvae, a tablet to deal with postpartum melancholy, for $469 million — lower than the $569 million in money that Sage has available as of September. The lowball provide is unlikely to be accepted, however Sage additionally has little leverage after a collection of scientific failures final 12 months worn out its analysis pipeline and decimated its inventory value.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
